Perez-Bermejo, Juan A. http://orcid.org/0000-0001-7625-358X
Efagene, Oghene
Matern, William M. http://orcid.org/0000-0001-9553-3771
Holden, Jeffrey K.
Kabir, Shaheen
Chew, Glen M. http://orcid.org/0000-0001-6186-4353
Andreoletti, Gaia http://orcid.org/0000-0002-0452-0009
Catton, Eniola
Ennis, Craig L.
Garcia, Angelica
Gerstenberg, Trevor L.
Hill, Kaisle A.
Jain, Aayami
Krassovsky, Kristina
Lalisan, Cassandra D.
Lord, Daniel
Quejarro, B. Joy
Sales-Lee, Jade
Shah, Meet
Silva, Brian J. http://orcid.org/0009-0009-2637-7723
Skowronski, Jason
Strukov, Yuri G.
Thomas, Joshua
Veraz, Michael
Vijay, Twaritha
Wallace, Kirby A.
Yuan, Yue http://orcid.org/0009-0009-7221-8299
Grogan, Jane L. http://orcid.org/0000-0003-4062-7134
Wienert, Beeke
Lahiri, Premanjali
Treusch, Sebastian
Dever, Daniel P.
Soros, Vanessa B.
Partridge, James R.
Seim, Kristen L. http://orcid.org/0009-0001-1578-4747
Article History
Received: 7 August 2023
Accepted: 6 March 2024
First Online: 23 March 2024
Competing interests
: All authors are current or former employees of Graphite Bio, Inc. and may own stock/options in the company. A patent application encompassing compositions of and methods for using the improved 53BP1 inhibitors has been filed with J.A.P.B., O.E., W.M.M., B.W., V.B.S., J.R.P. and K.L.S included as inventors and Graphite Bio, Inc. as the applicant (PCT/US2023/084675, pending).